SpringWorks Therapeutics (SWTX) Goldman Sachs 45th Annual Global Healthcare Conference summary

Key value drivers and product launches

• Ogsiveo launch for desmoid tumors is progressing well, with strong early patient benefit and broad prescriber adoption; 80% of centers of excellence have prescribed it.

• Over 98% of physicians with experience consider Ogsiveo first-line and standard of care; reimbursement is robust, with 98% of commercially covered lives reimbursed without restriction.

• Market opportunity for Ogsiveo is now viewed with higher conviction, supported by updated patient numbers and strong physician and patient feedback.

• NDA filing for mirdametinib in NF1-PN (pediatric and adult) is expected by mid-year, with a potential launch by next year.

• Ovarian granulosa cell tumor data is expected in the second half of the year, targeting a population with high unmet need.

Market dynamics and patient segmentation

• Desmoid tumor market includes 6,000–7,000 treated patients, 1,700 newly diagnosed annually, and 30,000 previously treated; patient uptake is steady rather than bolus due to disease rarity.

• Prescribers are proactively reaching out to previously diagnosed patients, and discontinuations remain low.

• Compliance and adherence are high, aided by new blister pack dosing options that simplify treatment.

• Growth is expected to be consistent, with new patients added each month and a stacking effect typical of rare disease therapies.

Competitive landscape and differentiation

• Ogsiveo is not limited by ovarian dysfunction concerns; real-world data shows high rates of symptom resolution, supporting use in women of childbearing potential.

• No new safety or tolerability issues have emerged beyond those seen in phase III; GI toxicity is managed proactively.

• In NF1-PN, mirdametinib is positioned as best-in-class for pediatrics and first-in-class for adults, with superior tolerability and efficacy compared to AstraZeneca's Koselugo.

• Physician surveys show over 96% prefer mirdametinib's profile, and patient-reported outcomes further differentiate the product.